Tohoku J. Exp. Med., 2009 , 217 (1), 29-35. © 2009 Lung cancer (LC) is currently the most common types of cancer in Japan. Of the estimated 123,000 cases of LC in Japan in 2006, 70% were 65 years or older, and healthcare expenditures for LC were $US2.63 billion (Ministry of Health, Welfare and Labor, 2006) . LC has been attracting attention both clinically and economically, as new chemotherapeutic agents and diagnostic imaging techniques continue to be developed (Dooms et al. 2006; Pimentel et al. 2006; Maniadakis et al. 2007; Ng et al. 2007; Spiro et al. 2008) . These advances in medical care have benefited LC patients (Oliver et al. 2001; Conron et al. 2007; Ostgathe et al. 2008) .
In developed countries where healthcare expenditures and the aging population are both experiencing rapid growth, a sustainable health care system is necessary. Consequently, a good deal of research in the health service on non-communicable diseases has focused on monitoring the quality and efficiency of medical care, as well as improving the quality of care through the introduction of multidisciplinary practice. When conducting health service research, several factors affecting resource use should be taken into account. Some factors are specific to a particular disease, cancer stage, or pathological diagnosis of a malignant neoplasm. Other variables are common to a wide range of diseases, although the impact of a particular variable may vary dramatically among them.
Although many LC studies have noted a difference in practice between patients with SCLC and those with NSCLC (Oliver et al. 2001; Dooms et al. 2006; Pimentel et al. 2006; Maniadakis et al. 2007; Ng et al. 2007; Ostgathe et al. 2008) , the study population were often limited to either small cell LC (SCLC) patients or non-small cell LC (NSCLC) patients. For effective management of health policy for the entire LC population, it is necessary to understand the effect of LC-related variables and prioritize these variables. In addition, clinical experts involved in health service research need to be reassured of the significance of relevant clinical information. Within that context, it is important to measure the effect of pathological diagnosis or cancer stage on resource use and practice differences. In the current study, we investigated differences in practice between SCLC and NSCLC patients and examined how LC-related severity, such as pathological diagnosis or cancer staging, impacts on costs.
MATERIALS AND METHODS
We utilized the Japanese administrative database gathered by the Ministry of Health, Labor and Welfare (MHLW) between July 1 and December 31, 2006. This database was created in order to develop Japanese case-mix grouping, refine the payment system, and disclose hospital performance for 731 institutions (80 university hospitals, the National Cancer Center, the National Cardiovascular Center, and 649 community hospitals). These hospitals serve various functions, including the delivery of acute care, advanced medical research, and/or the education of students and trainees. The database contains both discharge summaries and claims data in electronic format, which is useful for profiling detailed practice patterns. In the current study, we analyzed LC cases from hospitals that voluntarily participated in our research project. The study has been approved by the ethics committee of the University of Occupational and Environmental Health.
Definition of variables
The principal diagnosis recorded for the patients evaluated in this study was primary malignant respiratory neoplasm, according to the International Statistical Classification of Diseases, Version 10 (ICD10) (C33, C34 $). As pathological diagnosis was not listed in the ICD10 code, we collected information regarding pathology (SCLC, NSCLC, or unspecified) at admission, as advised by clinical experts. The independent variables analyzed were: use of an ambulance, hospital function, age, gender, diagnostic test, pathological diagnosis (SCLC and NSCLC), cancer stage classification (as an indicator of disease progression status at admission), status of comorbid conditions, procedure type, chemotherapeutic agents, and outcome. Use of an ambulance was used as a surrogate indicator of emergency admission. Patients were divided into two groups: patients < 65 years of age and those ≥ 65 years of age. The Charlson Comorbidity Index (CCI) was used to assess the degree of chronic comorbid conditions (Sundararajana et al. 2004) . Although the original CCI included primary respiratory cancer, this was not considered a chronic comorbid condition in the current study. Stage of LC was classified as 0 or 1, 2, 3, or 4, in accordance with the American Joint Committee on Cancer Staging System (Maddaus et al. 2005) . Various diagnoses in this database were recorded via ICD10 codes. The types of diagnostic imaging recorded included computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography, scintigraphy, and positron emission tomography (PET). Procedure-related complications were identified to be present if any of the ICD10 codes (T81$ through T87$), were recorded (Zhan et al. 2003) . The use of LC-related surgical procedures including resection (partial or wedge) or lobectomy for one lobe (referred to as lobectomy), video-assisted thoracic surgery (VATS), and either resection of at least 2 lobes or sleeve lobectomy (referred to as extended lobectomy) was recorded. Adjuvant therapy was divided into three categories; namely, chemotherapy only, radiation only, and chemo-radiation. The use of ten specific chemotherapeutic agents including etoposide (eto), amurubicin (amu), irinotecan (iri), docetaxel (doc), gefitinib (gef), carboplatin (car), paclitaxel (pac), cisplatin (cis), gemcitabine (gem), or vinorelbine (vin) was surveyed, and combinations of these chemo-agents were also investigated (Pimentel et al. 2006; Maniadakis et al. 2007; Ng et al. 2007; National Cancer Institution. 2008a , 2008b . In Japan, charges for hospital care are determined by a standardized fee-for-service payment system, and are considered to be good estimates of healthcare costs (Hirose et al. 2005) . This study used length of stay (LOS) and total charges (TC; US$1 = ¥100) billed during hospitalization as indicators of total inhospital cost. TC in our study included physician fees, instrument costs, laboratory costs, imaging tests or pharmaceutical agents, and administration fees.
Statistical analysis
Categorical data were reported as frequencies and proportions and were analyzed using Fisher's exact test. The Mann-Whitney test was used to compare differences in LOS or TC by pathological diagnosis. Effect of pathological diagnosis on LOS and TC was measured using a multiple linear regression model. In this model, distributions of LOS and TC were skewed to the right and log-transformed. Statistical analysis was performed using SPSS, Version 16.0. All reported p-values were two-tailed, with the level of significance set at 0.05.
RESULTS
Of the 20,567 LC patients analyzed, 14,507 were treated at 257 community hospitals and 6,060 at 58 academic hospitals. We identified 3,571 SCLC (17.4%) and 16,996 NSCLC patients (82.6%) ( Table 1 ). Of these, 1,002 SCLC and 5,058 NSCLC patients were treated at academic hospitals. The median age was 70 and 69 years for SCLC and NSCLC patients, respectively. The proportion of patients ≥ 65 years was 69.5% for SCLC and 63.4% for NSCLC patients, which was significantly different. Males composed 80.4% and 70.1% of the population of SCLC and NSCLC patients, respectively. Emergency status at admission was noted for 3.8% of SCLC and 3.2% of NSCLC patients ( p = 0.054). There were 1,939 cases of mortality, comprising 391 (10.9%) SCLC patients and 1548 (9.1%) NSCLC patients. The proportion of Stage 3 or Stage 4 patients varied significantly between SCLC (88.9%) and NSCLC patients (72.0%). A significant difference in the absence of chronic comorbidities (according to the CCI) between SCLC (43.7%) and NSCLC patients (49.5%) was also observed (Table 1) .
Use of diagnostic imaging is shown in Table 2 . CT was the most common diagnostic imaging technique, utilized in 53.3% of SCLC and 47.8% of NSCLC patients. MRI was the second most common imaging technique, utilized in 17.2% of SCLC and 14.7% of NSCLC patients. Chemotherapy only or chemo-radiation therapy was administered to significantly more SCLC compared with NSCLC patients (63.7% and 10.8%, respectively). Eto, car and cis were most frequently used chemotherapeutic agents in SCLC (36.8%, 34.8%, and 24.4%, respectively), whereas pac, gem and vin were so in NSCLC patients (18.0%, 10.4%, and 10.1%, respectively) ( Table 2) . As for combination chemotherapy, three regimens containing 4 chemotherapeutics (car + eto, cis + iri or cis + eto) were used in 60.6% of SCLC patients receiving any of the study chemotherapeutics. In comparison, seven combinations of chemotherapeutics were needed to reach 64% of cumulative relative frequency in NSCLC patients (car + pac, gef, doc, vin ± gem, cis + vin or car + gem) ( Table 3 ). The proportion of LC patients who underwent surgical procedures was significantly different between SCLC (2.7%) and NSCLC patients (18.2%) ( Table 2 ). Median LOS was significantly different between SCLC (20 days) and NSCLC patients (18 days). TC was also significantly different between SCLC (US$6,015) and NSCLC patients (US$6,993).
After controlling for demographic and clinical variables, the treatment categories 'radiation only or chemoradiation' were found to be significantly correlated with LOS and TC, whereby estimation values were 1.093 or 1.484 in LOS, and 1.057 or 1.506 in TC, respectively (Table 4) . Some surgical procedures were significantly correlated with TC, in that the estimation in TC for VATS or extended lobectomy was 1.769 or 1.743, respectively. Compared with the impact of other study variables, pathological diagnosis was statistically significant determinant of LOS, but not of TC.
DISCUSSION
Utilization of a Japanese administrative database from 315 hospitals allowed us to analyze practice patterns or costs with regard to pathological diagnosis of LC patients, and an independent effect of pathological diagnosis on LOS and TC. The patients' characteristics, use of diagnostic imaging, use of surgical procedures, combination of adjuvant therapy, or administration of chemotherapeutic agents varied significantly between SCLC and NSCLC patients. Impact of pathological diagnosis or cancer stage on LOS or TC was also modest or minimal, compared with that of other study variables.
Some limitations of this study should be noted. First, as we only analyzed in-hospital claims data, lack of outpatient department (OPD) data may have impacted the results. Our study did, however, initiate the gathering of OPD information in an electronic format, similar to that of the inpatient data. By combining databases, LC care events may eventually be tracked in the future, and researchers may identify a more realistic practice pattern. A second limitation was that laboratory data on respiratory function at admission were not surveyed, though the present study analyzed pertinent clinical data such as the Hugh Jones classification. Despite the fact that we did not examine respiratory function at admission, it is noteworthy for future studies that the collection of data on the use or prescribed number of bronchodilators may be possible surrogate markers for clinical severity of the disease. LOS for all acute care hospital admissions is reportedly two to three times longer in Japan (19.8 days in 2005) than in Western countries (5.4 days in France, 7.8 in United Kingdom, 8.5 in Switzerland) (OECD Health Data 2008) . One reason for the higher LOS in Japan is the lack of differentiation of hospital function. In general, Japanese hospitals provide rehabilitation and nursing home services in addition to acute medical care. The fiscal impact of these longer LOS includes higher actual costs consumed during each episode of LC (Ishizaki et al. 2002) . Therefore, the possibility of greater differences in cost between other relevant study variables, as well as between SCLC and NSCLC patients, could represent a strength of the present study.
Risk adjustment and clinical severity of disease should be considered in health policy research and the establishment of practice guidelines. Clinically relevant characteristics (e.g., age, comorbidities, cancer stage, and pathological diagnosis) often influence costs. Due to the growing financial burden of LC, many economic evaluations of new evolving pharmaceuticals, diagnostic and therapeutic technologies have been conducted (Dooms et al. 2006; Pimentel et al. 2006; Ng et al. 2007; Spiro et al. 2008) .
When investigating the quality or efficiency of particular LC treatments, many experts assume that clinical information would affect costs or practice pattern in the acute care setting. This type of research in LC, however, has largely been based on studies limited either to SCLC or NSCLC cases, and not on overall primary LC studies (Oliver et al. 2001; Conron et al. 2007; Ostgathe et al. 2008) . In cases where health services research for LC has been based on the entire LC population, it has often included either outpatient care or palliative medicine for LC (Conron et al. 2007; Podnos et al. 2007 ). We expect that some medical care might be common to all LC patients, whereas other types of medical care, such as chemotherapy, might be more specific to certain LC patients for whom the clinical severity of disease is higher. A thorough investigation of the effect of relevant elements including clinical information is therefore necessary for health policy to estimate healthcare Such an approach may result in a more efficient treatment pattern and better integration of care. In the field of palliative medicine for cancer patients, symptoms or quality of life might determine the nature of the care process or the amount of care, rather than the stage of cancer (Podnos et al. 2007; Ostgathe et al. 2008) . Conversely, if the impact of pathological diagnosis is too great to be disregarded, we need to observe practice guidelines and conduct further research on medical care for SCLC and NSCLC separately. This might enable institutions to examine their adherence to the guidelines and improve quality of care. This present study found a wide variation in the use of chemotherapy regimens, particularly for NSCLC patients, for whom there was no popular combination regimen, except for car + pac.
There remains a need to determine the optimal combination chemotherapy regimens for LC patients in Japan (Macbeth et al. 2007; Ostgathe et al. 2008) . Patient characteristics, choice of surgical procedure or adjuvant therapy, and administration of specific chemotherapeutics were significantly different, although pathological diagnosis or cancer stage had little, if any, association with LOS or TC. Clinical information relevant to disease severity should remain as indicators of whether administering adjuvant therapy is appropriate, including the use of chemotherapeutics.
In conclusion, the current study used an administrative database to present descriptive characteristics and analyze variation in resource use in SCLC and NSLC patients in Japan. The treatment pattern of chemotherapy was quite different in SCLC and NSLC patients. However, the independent effect of pathological diagnosis on TC was found to be not significant. Thus the value of using pathological diagnosis may be limited to monitoring the clinical validity of administering certain medications or performing certain procedures.
